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Abstract
AIM: To search for the answer in extensive ulcerative 
colitis as to whether histological inflammation per-
sisting despite endoscopic mucosal healing serves to 
increase the risk of colon cancer (CC) or high grade 
dysplasia (HGD).
METHODS: This is a single center (Lenox Hill Hospital) 
retrospective cohort and descriptive study of extensive 
ulcerative colitis (UC) for 20 years or more with a mini-
mum of 3 surveillance colonoscopies and biopsies per-
formed after the first 10 years of UC diagnosis. Data 
analyzed included: duration of UC, date of diagnosis of 
(CC) or (HGD), number of surveillance colonoscopies, 
and biopsies showing histological inflammation and its 
severity in each of 6 segments when endoscopic ap-
pearance is normal. Two subgroups of patients were 
compared: group 1 patients who developed CC/HGD 
and group 2 patients who did not develop CC/HGD.
RESULTS: Of 115 patients with longstanding UC re-
viewed, 68 patients met the inclusion criteria. Twenty 
patients were in group 1 and 48 in group 2. We identi-
fied the number of times for each patient when the 
endoscopic appearance was normal but biopsies nev-
ertheless showed inflammation. Overall, histological 
disease activity in the absence of gross/endoscopic 
disease was found in 31.2% (95%CI: 28%-35%) of 
colonoscopies performed on the entire cohort of 68 pa-
tients. Histological disease activity when the colonos-
copy showed an absence of gross disease activity was 
more common in group 1 than group 2 patients, 88% 
(95%CI: 72%-97%) vs  59% (95%CI: 53%-64%). 
Only 3/20 (15%) of patients in group 1 ever had a 
colonoscopy completely without demonstrated disease 
activity (i.e. , no endoscopic or histological activity) as 
compared to 37/48 (77%) of patients in group 2, and 
only 3.3% (95%CI: 0.09%-8.3%) of colonoscopies in 
group 1 had no histological inflammation compared to 
23% (95%CI: 20%-27%) in group 2.
CONCLUSION: Progression to HGD or CC in extensive 
ulcerative colitis of long standing was more frequently 
encountered among those patients who demonstrate 
persistent histological inflammation in the absence of 
gross mucosal disease. Our findings support including 
the elimination of histological inflammation in the defi-
nition of mucosal healing, and support this endpoint 
as an appropriate goal of therapy because of its risk of 
increasing dysplasia and colon cancer.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Histological healing favors lower risk of colon carcinoma in 
extensive ulcerative colitis
Burton I Korelitz, Keith Sultan, Megha Kothari, Leo Arapos, Judy Schneider, Georgia Panagopoulos
Korelitz BI et al . Histological inflammation increases risk of colon cancer in UC
Core tip: Patients with long standing and extensive 
ulcerative colitis who develop colon cancer rarely have 
histological healing despite gross endoscopic healing. 
The persistence of histological inflammation is common 
in those who develop colon cancer (CC) or high grade 
dysplasia (HGD). When surveillance colonoscopies in 
ulcerative colitis of 20 years duration reveal persistent 
histological inflammation, patients are at high risk for 
the development of CC/HGD. Consideration of increas-
ing drug therapy should arise, and the patient is en-
titled to share in this knowledge and contribute to the 
decision.
Korelitz BI, Sultan K, Kothari M, Arapos L, Schneider J, 
Panagopoulos G. Histological healing favors lower risk of colon 
carcinoma in extensive ulcerative colitis. World J Gastroenterol 
2014; 20(17): 4980-4986  Available from: URL: http://www.wjg-
net.com/1007-9327/full/v20/i17/4980.htm  DOI: http://dx.doi.
org/10.3748/wjg.v20.i17.4980
INTRODUCTION
Ulcerative colitis (UC) is one of  the two major chronic 
inflammatory bowel diseases, almost always involving the 
rectum and any or all segments of  the colon proximally 
in continuity. It is recognized that long-standing UC car-
ries an increased risk for the development of  colorectal 
carcinoma (CC) and high grade dysplasia (HGD), with 
estimates of  risk as high as 20% following 30 years of  
diagnosis[1]. This risk appears to be especially prominent 
in cases of  universal UC, which has traditionally been 
defined by endoscopic evidence of  disease proximal to 
the mid-transverse colon on at least one occasion follow-
ing diagnosis. Chronic macroscopic disease activity has 
also been implicated as a risk factor for the development 
for CC[2]. These observations have led to the practice of  
surveillance by colonoscopy in cases of  universal UC. 
Current practice guidelines recommend that surveillance 
be performed every 1-2 years in these patients beginning 
8-10 years after the initial UC diagnosis[3]. Surveillance 
typically involves four-quadrant biopsies of  the colon, 
either every 10 cm during withdrawal from the cecum, 
or by colonic segments (e.g., cecum, ascending colon, etc.) 
as well as biopsies of  specific lesions when encountered.
While it is generally accepted that extent, duration 
and chronicity of  inflammation directly impact cancer 
risk, less well studied is the role of  the PERSISTENCE 
of  microscopic inflammation after gross inflammation 
has subsided in the pathogenesis of  colon cancer[4-6]. Re-
cent case control and cohort studies have shown that the 
severity of  microscopic inflammation is also associated 
with an increased risk for colorectal neoplasia[7,8]. Rutter 
et al[7] noted that both endoscopic and histological sever-
ity of  disease impacted cancer risk on univariate analysis, 
only histological severity continued to show an increased 
risk for neoplasia following multivariate analysis.
In patients with inflammatory bowel disease (IBD), 
clinical remission is valuable for quality of  life but does 
not necessarily correlate with “mucosal healing”[9]. In-
creasingly, disease and treatment outcomes for IBD are 
being assessed in terms of  mucosal healing, which in 
most trials is defined by the normal appearance of  the 
colonic mucosa as described by the endoscopist at colo-
noscopy[10-13]. Nevertheless, histological inflammation 
of  varying degrees is common even when the mucosa 
appears normal. Though some may consider normal 
appearing mucosa as healed, it is unknown whether his-
tological disease activity even in the absence of  gross 
disease carries an increased risk for the development of  
CC or HGD.
To help answer this question we conducted a retro-
spective cohort descriptive study of  long-standing uni-
versal UC patients. Our primary goal was to determine if  
there was a relationship between histological disease ac-
tivity and risk for CC and HGD in the absence of  gross 
inflammation. Our secondary goal was to define the in-
cidence of  histological disease activity in the absence of  
gross disease activity, possibly predisposing to the later 
development of  high grade dysplasia or colon cancer.
MATERIALS AND METHODS
This is a study of  UC patients utilizing the inflammatory 
bowel disease data base of  over 3000 patients followed 
by the senior investigator Korelitz BI at Lenox Hill Hos-
pital over a 50 year period. Inclusion criteria required 
a diagnosis of  universal UC defined by the presence 
of  endoscopically active disease proximal to the mid-
transverse colon on at least one colonoscopy following 
the date of  UC diagnosis.
Candidates were only included if  they had at least 3 
surveillance colonoscopies performed following 10 years 
of  UC diagnosis and a minimum of  an additional 10 
years (total ≥ than 20 years of  disease). Data recorded 
included gender, age at diagnosis, year of  diagnosis, and 
disease duration. A Microsoft excel spreadsheet was 
constructed documenting each surveillance colonoscopy, 
recording the presence or absence of  gross endoscopic 
disease, and the presence or absence of  microscopic 
inflammation in those macroscopically normal in each 
colonic segment to include the cecum, ascending colon, 
transverse colon, descending colon, sigmoid colon and 
rectum. No specific index system for histological inflam-
mation was used since none was available during most 
of  the study period. The slides had been read by the 
institutional pathologists who all had extensive experi-
ence with surveillance biopsies in ulcerative colitis. All 
cases of  dysplasia were reviewed by a second pathologist 
specializing in gastrointestinal diseases. Each subject’s 
follow-up continued until either colectomy, the finding 
of  CC/HGD, or a duration of  at least 10 additional years 
of  surveillance after the first 10 years of  disease up until 
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Table 1  Demographics, decades of surveillance, and probable 
influence of advances in drug therapy
the final documented surveillance examination. All colo-
noscopies were performed by the Senior Author alone or 
with Fellows in Gastroenterology.
Ethical considerations
This study received approval of  the Institutional Review 
Board of  Lenox Hill Hospital on September 15, 2009.
Statistical analysis
This is a retrospective cohort and descriptive study, of  
greater than 20 year duration, which was undertaken to 
assess the frequency and extent to which histological 
inflammation is present in the absence of  gross endo-
scopic findings amongst patients with long-standing 
ulcerative colitis and whether this observation is more 
prevalent amongst patients who later develop colon 
cancer or high grade dysplasia. We report the observed 
prevalence of  histological inflammation and its associ-
ated 95%CI in the total cohort and the two groups; the 
group which later developed colon cancer/dysplasia and 
the group which did not.
These important observations result from a study the 
strength of  which is its long standing duration and the 
relative limited variation associated with a single prac-
tice. Obviously, its retrospective nature places the usual 
number of  anticipated limitations so that the conclu-
sions must be viewed with caution and taken to generate 
a hypothesis. Due to the long standing duration required 
to develop such a study, a prospectively controlled ex-
amination of  this question in order to confirm these 
observations is not feasible.
RESULTS
Of  115 patients with longstanding UC reviewed, 68 pa-
tients met the inclusion criteria. 47 were excluded either 
for lack of  the minimum of  20 years of  surveillance or 
less than 3 documented colonoscopies during the second 
10 years of  ulcerative colitis. Patients were subsequently 
divided into two groups, group 1 which was comprised 
of  20 patients who developed CC and/or HGD, and 
group 2 comprised of  48 patients who did not. Demo-
graphic data are summarized in Table 1. Overall, groups 
1 and 2 were similar in terms of  gender, age of  UC 
diagnosis and disease duration. More of  the patients in 
group 2 were diagnosed and treated in recent decades 
than those in group 1.
Table 1 notes the decade during which the diagnosis 
of  extensive ulcerative colitis was recognized and records 
the percentage of  patients treated with immunosuppres-
sives and/or biological during these decades.
Table 2 charts the number of  surveillance colonos-
copies done after 10 years of  disease for Groups 1 and 
2 and identifies the number of  times for each when the 
endoscopic appearance was normal but biopsies never-
theless showed inflammation. The 20 patients in group 
1 had 120 surveillance colonoscopies, range 3-14, me-
dian 4. Of  the 48 patients of  group 2, 550 surveillance 
colonoscopies were performed, range 3-28, median 8.5. 
Overall, histological disease activity in the absence of  
gross/endoscopic disease was found in 31.2% (95%CI: 
28%-35%) of  colonoscopies performed on the entire 
cohort of  68 patients. Histological disease activity when 
the colonoscopy showed an absence of  gross disease 
activity was more common in group 1 than group 2 
patients, 88% (95%CI: 72%-97%) vs 59% (95%CI: 
53%-64%). Only 3/20 (15%) of  patients in group 1 ever 
had a colonoscopy completely without demonstrated 
disease activity (i.e., no endoscopic or histological activ-
ity) as compared to 37/48 (77%) of  patients in group 2.
Among the 20 patients who developed CC/HGD, 17 
(85%)(95%CI: 62%-98%) were found distal to the splen-
ic flexure, including 11 (55%)(95%CI: 31%-37%) which 
developed in the rectum. In only 2 of  the 20 cases (10%) 
(95%CI: 1%-32%) was carcinoma (CA)/HGD found 
isolated proximal to the descending colon. In no case 
was CA/HGD found in a colonic segment without prior 
histological inflammation. Table 3 shows the segments of  
the colon involved with histological inflammation when 
the colonic mucosa appeared normal and the degree of  
inflammation on a progressive scale of  1-5. The severity 
of  inflammation was much more marked in group 1 than 
group 2. In these 20 patients of  group 1 who did develop 
neoplasia, both the persistence of  histological inflamma-
tion and its severity was most marked in the rectum and 
sigmoid where 12 of  the cases of  cancer (70.6%) and 10 
with severe dysplasia were found. This finding was similar 
to that reported by Goldstone et al[14] In only 2 of  the 20 
patients was CC/HGD found isolated proximal to the 
descending colon and in no case was it found without 
there having been previous inflammation. The severity 
of  inflammation was greater in all segments of  group 
1 than group 2. Features of  the 20 patients with high 
grade dysplasia and/or colon cancer are shown in Tables 
4 and 5.
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Characteristics Group 1 
CA/HGD
Group 2 
Non-CA/HGD
n = 68 20 48
Gender (% female)    50%    46%
Age at diagnosis (yr), range 27.3 (8-51)  25 (6-61)
Disease duration (yr), range   27.3 (12-54) 29.6 (16-48)
Treatment with 6 MP/IFX
Subjects/decades of diagno-
sis of UC
Subjects received1 Subjects received2
1930-1949 1   0
1950-1959 1   0
1960-1969 7   5
1970-1979 9 17
1980-1989 2 16
1990-1999 0 10
11970-1989, 6-mercaptopurine (6MP) = 55%, infliximab (IFX) = 0%; 
21960-1999, 6MP = 79%; 1980-1999, IFX = 27%. CA: Carcinoma; HGD: 
High-grade dysplasia; UC: Ulcerative colitis.
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Table 3  Segments of colon showing histological inflammation 
and its degree when endoscopically normal
Table 2  Summary of colonoscopic outcomes with and without neoplasia  n  (%)
DISCUSSION
Our study demonstrates an incidence of  CC/HGD of  
almost 30% following average disease duration of  over 
27 years. While this finding in a tertiary care/IBD spe-
cialty practice may not reflect community norms, it is 
clearly in line with the incidence in prior observations[1,6]. 
While others have examined the risk of  CC and dys-
plasia as a function of  duration, extent and severity of  
inflammation, our goal was to examine whether the per-
sistence of  microscopic inflammation was itself  a risk 
factor. We found that microscopic disease in the absence 
of  macroscopic disease was a common finding on sur-
veillance in the group who developed CC/HGD as well 
as the group who did not. However, a finding of  both 
endoscopic and histological healing was a rare event in 
the CC/HGD group (3.3% of  colonoscopies) vs the 
non-CC/HGD group (23% of  colonoscopies), and that 
few patients in group 1 would ever demonstrate micro-
scopic mucosal healing (15%), while a majority of  those 
in group 2 would at some point during their follow up 
(77%). Furthermore, the severity of  inflammation was 
much greater for all biopsied segments for group 1 than 
group 2. These findings add to those earlier observations 
by reinforcing the prognostic benefits of  histological 
mucosal healing in addition to gross mucosal healing.
Additionally, we sought to determine the incidence 
of  histological disease activity when gross mucosal 
healing was observed. Overall, we found that 31.2% 
(95%CI: 28%-35%) of  all colonoscopies that demon-
strated grossly normal appearing colonic mucosa also 
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Colonoscopic outcome Group 1 Group 2 Total 
(n  = 20) (n  = 48) (n  = 68)
Colonoscopies after 10 yr of UC 120 550 670
Range 3-14 median 6 Range 3-28 median 11.5
Colonoscopies with endoscopically active colitis    87 (72.5)    243 (44.2) 330 (49.2)
Colonoscopies without endoscopically active colitis but with histological inflammation1    29 (24.2)    180 (32.7) 209 (31.2)
Colonoscopies without gross/endoscopic or histological inflammation    4 (3.3)    127 (23.1) 131 (19.6)
% of endoscopically negative colonoscopies with histological inflammation2 29 (88) 180 (59)
1Prevalence in all colonoscopies; 2Prevalence in all colonoscopies. UC: Ulcerative colitis.
Case-index Cecum Asc colon Trans 
colon
Desc 
colon
Sigmoid Rectum
1N 2 2 2 2 2 2, 4, 5
2N 2, 4 2, 4 2 2, 4 2, 4 2, 4
3N 3 3 3 3 3 3, 4
4N 1 1 1 1 1, 5 1, 5
5N 3 3 3 3, 4 3, 5 3, 4, 5
6N 2 2 3, 5 3 3, 5 2
7N 1 1 1 1 2, 4, 5 2, 4
8N 2 2 3, 5 3 3, 5 2
9N 2 2 2 2 2, 4 2, 4
10N 3 3 3 3, 4 3 3
11N 3 3 3 3 3,5 3
12N 1 1, 5 1, 4, 5 2 2 2
13N 3, 5 3, 5 3 3 3 3
14N 1 2, 5 2, 4 2, 4 1, 4 1
15N 2 2 2 2, 5 2 2
16N 2 2 2 3 3, 4, 5 3, 5
17N 2 2 2 3 3 3, 5
18N 1 1 1 1 2, 4, 5 2
19N 3 3 3 3 3 3, 5
20N 3 3 3 3 3, 4, 5 3, 5
1 1 1 3 2 3 3
2 0 0 0 0 0 1
3 0 0 1 1 0 1
4 2 0 1 1 0 3
5 1 0 2 2 2 2
6 3 3 0 0 1 2
7 0 0 0 0 0 0
8 2 2 0 0 1 1
9 0 0 1 1 1 1
10 1 1 1 1 1 1
11 1 1 1 1 1 1
12 0 1 2 2 2 1
13 1 1 3 2 2 0
14 0 0 0 0 0 0
15 1 0 0 1 1 1
16 0 0 2 1 1 0
17 1 2 2 2 2 2
18 0 0 0 0 0 0
19 1 1 1 1 1 1
20 2 2 0 2 2 0
21 2 0 2 2 1 2
22 0 0 1 1 1 1
23 1 1 1 1 0 0
24 1 1 1 1 1 0
25 0 0 1 1 2 2
26 1 1 1 3 0 2
27 0 0 2 2 2 2
28 1 1 1 2 1 1
29 1 1 2 1 1 3
30 1 1 1 1 1 1
31 0 0 0 1 1 1
32 2 0 2 2 1 1
33 2 2 0 2 2 2
34 0 0 0 1 0 0
35 1 1 1 3 1 1
36 1 1 1 2 3 2
37 1 1 0 0 2 2
38 0 0 1 1 1 0
39 1 1 1 1 1 0
40 1 1 1 1 2 2
41 0 0 3 0 0 0
42 1 0 2 2 2 2
43 1 1 1 0 1 1
Group 1 = 1N→20N (29 colonoscopies); Group 2 = 1→43 (180 colonosco-
pies). Degree of inflammation: 0, none; 1, mild; 2, moderate; 3, severe; 4, 
dysplasia; 5, cancer.
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Table 5  Features of the patients with carcinoma of colon
Table 4  Features of 20 patients with high grade dysplasia or carcinoma of colon
demonstrated evidence of  microscopic inflammation. 
To the experienced IBD gastroenterologist this finding 
will come as no surprise. The persistence of  histological 
inflammation in ulcerative colitis without evident clinical 
activity or abnormal endoscopic appearance was report-
ed over 50 years ago by Truelove and Richards[15], Dick 
and Grayson[16] and Matts[17]. Later Morson[18] and Dick 
et al[19] further popularized the value of  rectal biopsies 
and Sommers et al[20] and Korelitz et al[21] introduced the 
technique of  mucosal cell counts for evaluating persis-
tence of  inflammation and for response to specific drug 
therapy. Their findings were based mostly on finding an 
excess of  chronic inflammatory cells including plasma 
cells and an apparent increase in polymorphonuclear leu-
kocytes. Riley et al[22] reported the risk of  relapse in UC 
when biopsies showed any acute inflammatory infiltrate 
histologicallyand Bitton et al[23] showed that the findings 
of  plasmacytes on biopsy specifically increased the likeli-
hood of  relapse. Bessissow et al[24] suggested optimizing 
medical therapy when this finding is disclosed.
Discussion on the value of  surveillance for ulcerative 
colitis provides a wide range of  opinions. Higgins et al[25] 
and Dhanda et al[26] raise the option of  eliminating colo-
noscopy entirely since it contributes little to the degree 
of  ulcerative colitis activity beyond clinical activity as 
reported by the patient; we feel that this should pertain 
only to an index of  activity but not to surveillance for 
dysplasia and cancer. Rutgeerts et al[27], Regueiro et al[9], 
and Pineton de Chambrun et al[13] emphasize the lack of  
correlation between clinical and endoscopic findings and 
support endoscopic healing for clinical trials but do not 
include histological healing as a component of  mucosal 
healing for surveillance purposes. Baars et al[28] found an 
incidence of  histological inflammation of  49% when the 
mucosa appeared endoscopically normal. Rutter et al[7], 
Gupta et al[8] and Mathy et al[29] have recognized the im-
portance of  histological inflammation in providing a risk 
factor for colon cancer in long-standing ulcerative colitis 
and propose the inclusion of  microscopic inflammation 
in a grading system for risk stratification. Such histologi-
cal grading scales have been proposed by Geboes et al[30] 
and Korelitz[31].
The most notable drawback to our own analysis is 
the discrepancy between the numbers of  surveillance 
colonoscopies performed between the two groups, with 
a median number of  examinations more than double in 
group 2 who did not develop HGD/CC. While more ex-
aminations decreased the chance of  missing HGD/CC, 
it also increased the number of  opportunities for the pa-
tients in the non-CC/HGD group to show histological 
mucosal healing. As such, it is likely that the percentage 
of  individuals who had a colonoscopy with complete 
mucosal healing would have been less if  this groups’ sur-
veillance frequency was closer to the HGD/CC group.
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Case High grade dysplasia Multiple sites of dysplasia Low grade dysplasia Colon cancer Location of cancer
1 + 1 0 0 -1
2 + 1 0 0 -1
3 + 0 0 0 -1
4 + 0 0 + Recto-sigmoid
5 + 1 0 + Sigmoid
6 + 1 0 + Sigmoid
7 + 1 0 + Sigmoid
8 0 0 0 + Distal transverse
9 0 1 1 + Ileo-Anal pouch
10 + 1 0 + Sigmoid
11 0 0 0 + Sigmoid
12 0 0 0 + Prox transverse
13 + 1 1 + Cecum
14 0 0 1 + Ascending
15 0 0 0 + Descending
16 + 0 1 + Recto-sigmoid
17 + 1 1 + Rectum
18 0 0 0 + Sigmoid
19 0 0 0 + Rectum
20 + 0 0 + Sigmoid
Totals 12 9 5 17
1High grade dysplasia at multiple sites, not cancer.
Features Colectomies
Cancer discovered at endoscopy led to colectomy 8
Colectomy for high grade dysplasia also disclosed 
cancer
8
Colectomy for high grade dysplasia did not disclose 
cancer 
3
Cancer discovered by metastases (no colectomy) 1
Most cancers in sigmoid and rectum 12/17
Multiple areas of dysplasia 6
Low grade as well as high grade dysplasia 6
Alive in 2012 9
High grade dysplasia at multiple sites, not cancer 3/20
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Also, our comparison of  the two groups does not 
account for possible treatment differences. It is notable 
that most of  the patients in the non-CC/HGD group 
were diagnosed and received treatment during an era of  
increasing use of  immunosuppressive and then biolog-
ics to treat UC, suggesting a beneficial effect of  such 
therapy. We have previously shown a trend toward a re-
duced risk for colon cancer in IBD patients treated with 
6-mercaptopurine (MP)[32] but were unable to confirm 
this statistically though a more recent analysis of  the 
CESAME cohort has shown a significant decrease in 
the incidence of  colon cancer in patients with extensive 
colitis[33] treated with thiopurines. In the present study, 
we show that the decades of  treatment with 6 MP alone 
coincide with reduced risk of  neoplasia (6 MP used in 
79% of  group 2 vs 55% in group 1) and similarly with 
infliximab (27% in group 2 vs none in group 1). Though 
others have observed an association between CC and de-
cade of  disease diagnosis, the relationship of  treatment 
with 5-amino salicylic acid preparations and CC/HGD 
rates in UC remains controversial, as the continuing pro 
and con debate surrounding their role in CC prevention 
bears out[34-37].
In conclusion, our findings clearly add to the argu-
ment in favor of  defining mucosal healing not only by 
endoscopic findings, but by histological healing as well. 
Confirmation of  gross mucosal healing has been advo-
cated as an appropriate and objective measure of  suc-
cessful treatment in clinical trials[38,39], but this definition 
of  mucosal healing remains controversial[10,11,39,40]. Our 
findings confirm previously reported high rates of  CC/
HGD in patients with longstanding extensive colitis. We 
show that progression to CC/HGD appears to be less 
common in those patients who demonstrate histologi-
cal mucosal healing compared to those who persistently 
show microscopic disease activity. The endoscopist 
should acknowledge that endoscopic healing and histo-
logical healing are not synonymous and surveillance bi-
opsies should be performed even when the endoscopic 
appearance is normal, and the results should be a part 
of  patient counseling regarding the goals and expected 
outcomes in this high risk group.
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therapy because of its risk of increasing dysplasia and colon cancer.
Peer review
This is an interesting manuscript investigating the importance of histologic 
inflammation in the development of HGD/CRC in UC. The evidence presented 
here adds support to the fact that persistence of microscopic inflammation in-
creases the risk of colon cancer in ulcerative colitis.
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